United States Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The United States Diabetes Drugs and Devices Market is Segmented by Drugs (insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs) and Devices (management Devices Such As Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors, and Monitoring Devices Including Self-Monitoring Blood and Continuous Glucose Monitoring). The Report Offers the Value (in USD) and Volume (in Unit) for the Above Segments.

United States Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

US Diabetes Drugs and Devices Market Size

US Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 62.52 Billion
Market Size (2030) USD 76.07 Billion
CAGR (2025 - 2030) 4.00 %

Major Players

US Diabetes Drugs And Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of US Diabetes Drugs And Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

US Diabetes Drugs and Devices Market Analysis

The US Diabetes Drugs And Devices Market size is estimated at USD 62.52 billion in 2025, and is expected to reach USD 76.07 billion by 2030, at a CAGR of greater than 4% during the forecast period (2025-2030).

People with diabetes are at a heightened risk of experiencing serious complications from COVID-19 and face a 300% increased risk of being hospitalized compared to those without diabetes. This can result in significantly higher healthcare costs, prompting doctors and the government to urge people with diabetes to check their glucose levels regularly.

Diabetes, a persistent and potentially fatal ailment lacking a cure, affects a staggering number of individuals worldwide. According to the World Health Organization, the global population of people living with diabetes exceeds 400 million, and the expenses incurred for its treatment account for approximately 12% of the overall healthcare expenditure. This condition has rapidly spread as a worldwide epidemic, afflicting millions across the globe. The substantial expansion of the diabetes market can be attributed to several factors, including the escalating prevalence of diabetes and the implementation of numerous health awareness programs by various organizations. Presently, Type-1 diabetes accounts for approximately 10% of all diabetes cases, while the remaining majority falls under Type-2.

People with diabetes are more likely to develop severe symptoms and complications when infected with the virus. According to AACE (American Association for Clinical Endocrinology), a recent study reported that 22.2-26.9% of those hospitalized with serious illness had diabetes. Diabetes and hyperglycemia are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

The pandemic has also highlighted opportunities to continue and expand innovation in diabetes care through virtual consultations between healthcare providers and people with diabetes and using diabetes technology. Crisis management has led to unprecedented interest in telemedicine from patients and healthcare professionals, removing many long-standing regulatory barriers. Thus, the outbreak of novel coronavirus disease (COVID-19) has fueled the growth of the diabetes care equipment market.

US Diabetes Drugs and Devices Industry Overview

Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices.

US Diabetes Drugs and Devices Market Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
US Diabetes Drugs and Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

US Diabetes Drugs and Devices Market News

  • June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education.
  • January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.

US Diabetes Drugs And Devices Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Segmentation

  • 5.1 Devices
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-monitoring Blood Glucose Devices
    • 5.1.1.2 Continuous Blood Glucose Monitoring
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pump
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Cartridges
    • 5.1.2.4 Disposable Pens
  • 5.2 Drugs
    • 5.2.1 Oral Anti-Diabetes Drugs
    • 5.2.2 Insulin Drugs
    • 5.2.3 Combination Drugs
    • 5.2.4 Non-Insulin Injectable Drugs
  • 5.3 Distribution Channel
    • 5.3.1 Online
    • 5.3.2 Offline

6. Market Indicators

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novartis
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Astrazeneca
    • 7.1.12 Dexcom
    • 7.1.13 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

US Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times a day, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. The United States diabetes care drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Devices Monitoring Devices Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Distribution Channel Online
Offline
Need A Different Region or Segment?
Customize Now

US Diabetes Drugs And Devices Market Research Faqs

How big is the US Diabetes Drugs And Devices Market?

The US Diabetes Drugs And Devices Market size is expected to reach USD 62.52 billion in 2025 and grow at a CAGR of greater than 4% to reach USD 76.07 billion by 2030.

What is the current US Diabetes Drugs And Devices Market size?

In 2025, the US Diabetes Drugs And Devices Market size is expected to reach USD 62.52 billion.

Who are the key players in US Diabetes Drugs And Devices Market?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the US Diabetes Drugs And Devices Market.

What years does this US Diabetes Drugs And Devices Market cover, and what was the market size in 2024?

In 2024, the US Diabetes Drugs And Devices Market size was estimated at USD 60.02 billion. The report covers the US Diabetes Drugs And Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the US Diabetes Drugs And Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

US Diabetes Drugs And Devices Industry Report

Statistics for the 2025 US Diabetes Drugs And Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. US Diabetes Drugs And Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.